ERBB2 and breast carcinoma: As we mentioned at the beginning of the section, even though active vaccination therapy for HER2+ breast cancer has several theoretical advantages, clinical trials evaluating breast cancer vaccines have provided limited evidence of clinical benefits despite the successful induction of immune responses [435].